| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frontiers in Nephrology |

* Department of Medicine, Division of General Internal Medicine, Maastricht University and University Hospital Maastricht, Maastricht, and
Department of Internal Medicine and Institute for Cardiovascular Research, Vrye Universiteit University Medical Center, Amsterdam, The Netherlands
Address correspondence to: Dr. Coen D.A. Stehouwer, Department of Medicine, Maastricht University and University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands. Phone: +31-43-3877006; Fax: +31-43-38750006; E-mail: csteh{at}sint.azm.nl
Microalbuminuria is a strong and independent indicator of increased cardiovascular risk among individuals with and without diabetes. Therefore, microalbuminuria can be used for stratification of risk for cardiovascular disease. Once microalbuminuria is present, cardiovascular risk factor reduction should be more "aggressive." The nature of the link between microalbuminuria and cardiovascular risk, however, remains poorly understood. There is no strong evidence that microalbuminuria causes atherothrombosis or that atherothrombosis causes microalbuminuria. Many studies have tested the hypothesis that a common risk factor underlies the association between microalbuminuria and cardiovascular disease but, again, have found no strong evidence in favor of this contention. At present, the most likely possibility is that a common pathophysiologic process, such as endothelial dysfunction, chronic low-grade inflammation, or increased transvascular leakage of macromolecules, underlies the association between microalbuminuria and cardiovascular disease, but more and prospective studies of these hypotheses are needed.
This article has been cited by other articles:
![]() |
R. Shibata, S. Ueda, S.-i. Yamagishi, Y. Kaida, Y. Matsumoto, K. Fukami, A. Hayashida, H. Matsuoka, S. Kato, M. Kimoto, et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy Nephrol. Dial. Transplant., November 17, 2008; (2008) gfn630v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hadjadj, F. Fumeron, R. Roussel, P.-J. Saulnier, Y. Gallois, A. Ankotche, F. Travert, C. A. Khalil, A. Miot, F. Alhenc-Gelas, et al. Prognostic Value of the Insertion/Deletion Polymorphism of the ACE Gene in Type 2 Diabetic Subjects: Results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies Diabetes Care, September 1, 2008; 31(9): 1847 - 1852. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Suliman, M. I. Yilmaz, J. J. Carrero, A. R. Qureshi, M. Saglam, O. M. Ipcioglu, M. Yenicesu, M. Tong, O. Heimburger, P. Barany, et al. Novel Links between the Long Pentraxin 3, Endothelial Dysfunction, and Albuminuria in Early and Advanced Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 976 - 985. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.E. Suliman, A.R. Qureshi, J.J. Carrero, P. Barany, M.I. Yilmaz, S. Snaedal-Jonsdottir, A. Alvestrand, O. Heimburger, B. Lindholm, and P. Stenvinkel The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality QJM, May 1, 2008; 101(5): 397 - 405. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schiffrin, M. L. Lipman, and J. F.E. Mann Chronic Kidney Disease: Effects on the Cardiovascular System Circulation, July 3, 2007; 116(1): 85 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. B. Nanayakkara, C. van Guldener, P. M. ter Wee, P. G. Scheffer, F. J. van Ittersum, J. W. Twisk, T. Teerlink, W. van Dorp, and C. D. A. Stehouwer Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease: Results From the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study Arch Intern Med, June 25, 2007; 167(12): 1262 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Weir Microalbuminuria and Cardiovascular Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 581 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Matsumoto, S. Ueda, S.-i. Yamagishi, K. Matsuguma, R. Shibata, K. Fukami, H. Matsuoka, T. Imaizumi, and S. Okuda Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1525 - 1533. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. de Zeeuw, H.-H. Parving, and R. H. Henning Microalbuminuria as an Early Marker for Cardiovascular Disease J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2100 - 2105. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673